Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 971–980 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 971
- Medicine slug
- methylergonovine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
60%
- Numeric value
- 60
- Unit
- %
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f04ca06-fe52-46d6-96cd-2e77ef6fa36f (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7ec8dfe-9b58-4363-a709-c1b72ee67855 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ddcdfff-1468-bff0-e063-6294a90a5480 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b49b1e4c-de20-446d-b80a-75c7f0d41ddf (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bccff44-2a39-400a-b8a4-2eb5249fdbc8 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:465b292b-0e0e-4a55-894e-90234efe2a12 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:885b98d9-ba2c-48fb-b3b8-940e5f5e93d6 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The bioavailability after oral administration was reported to be about 60%, with no accumulation after repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98ad5af1-bde6-4137-a599-b6354d664da4 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17ee0c79-ac98-4400-ae77-985978fca07e (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9a3079e-b62b-4858-920e-d8f5cb38481e (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a6fe76c-d709-419e-885e-fa2ce07df27b (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The bioavailability after oral administration was reported to be about 60%, with no accumulation after repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8e4b8ed-3289-4611-8a61-2392a4bf6072 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a318b77-d280-4571-992f-82e2e0a57c9b (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7f19e89-8b52-4033-9914-f3b41fe0790d (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4c48277-eb9e-6150-e053-2a95a90ab21d (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The bioavailability after oral administration was reported to be about 60%, with no accumulation after repeated doses.
Projected row 972
- Medicine slug
- methylergonovine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
3.39 hours
- Numeric value
- 3.39
- Unit
- hours
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f04ca06-fe52-46d6-96cd-2e77ef6fa36f (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The plasma level decline was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7ec8dfe-9b58-4363-a709-c1b72ee67855 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The decline of plasma level of intramuscularly administered methylergonovine was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ddcdfff-1468-bff0-e063-6294a90a5480 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The decline of plasma level of intramuscularly administered methylergonovine was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b49b1e4c-de20-446d-b80a-75c7f0d41ddf (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The decline of plasma level of intramuscularly administered methylergonovine was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bccff44-2a39-400a-b8a4-2eb5249fdbc8 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The decline of plasma level of intramuscularly administered methylergonovine was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:465b292b-0e0e-4a55-894e-90234efe2a12 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The decline of plasma level of intramuscularly administered methylergonovine was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:885b98d9-ba2c-48fb-b3b8-940e5f5e93d6 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The plasma level decline was biphasic, with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98ad5af1-bde6-4137-a599-b6354d664da4 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The plasma level decline was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17ee0c79-ac98-4400-ae77-985978fca07e (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The decline of plasma level of intramuscularly administered methylergonovine was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9a3079e-b62b-4858-920e-d8f5cb38481e (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The decline of plasma level of intramuscularly administered methylergonovine was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a6fe76c-d709-419e-885e-fa2ce07df27b (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The plasma level decline was biphasic, with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8e4b8ed-3289-4611-8a61-2392a4bf6072 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The decline of plasma level of intramuscularly administered methylergonovine was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a318b77-d280-4571-992f-82e2e0a57c9b (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The plasma level decline was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7f19e89-8b52-4033-9914-f3b41fe0790d (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The decline of plasma level of intramuscularly administered methylergonovine was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4c48277-eb9e-6150-e053-2a95a90ab21d (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The plasma level decline was biphasic, with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).
Projected row 973
- Medicine slug
- methylergonovine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
1.12 ± 0.82 hours
- Numeric value
- 1.12
- Unit
- hours
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f04ca06-fe52-46d6-96cd-2e77ef6fa36f (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7ec8dfe-9b58-4363-a709-c1b72ee67855 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3,243 ± 1,308 pg/mL observed at 1.12 ± 0.82 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ddcdfff-1468-bff0-e063-6294a90a5480 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b49b1e4c-de20-446d-b80a-75c7f0d41ddf (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bccff44-2a39-400a-b8a4-2eb5249fdbc8 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:465b292b-0e0e-4a55-894e-90234efe2a12 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:885b98d9-ba2c-48fb-b3b8-940e5f5e93d6 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid, with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98ad5af1-bde6-4137-a599-b6354d664da4 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17ee0c79-ac98-4400-ae77-985978fca07e (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9a3079e-b62b-4858-920e-d8f5cb38481e (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a6fe76c-d709-419e-885e-fa2ce07df27b (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid, with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8e4b8ed-3289-4611-8a61-2392a4bf6072 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a318b77-d280-4571-992f-82e2e0a57c9b (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7f19e89-8b52-4033-9914-f3b41fe0790d (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4c48277-eb9e-6150-e053-2a95a90ab21d (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid, with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.
Projected row 974
- Medicine slug
- methylergonovine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
56.1 ± 17.0 liters
- Numeric value
- 56.1
- Unit
- L
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f04ca06-fe52-46d6-96cd-2e77ef6fa36f (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The volume of distribution (Vd ss /F) of methylergonovine was calculated to be 56.1 ± 17.0 liters, and the plasma clearance (CLp/F) was calculated to be 14.4 ± 4.5 liters per hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:885b98d9-ba2c-48fb-b3b8-940e5f5e93d6 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The volume of distribution (Vd SS /F) of methylergonovine was calculated to be 56.1 ± 17.0 liters, and the plasma clearance (CLp/F) was calculated to be 14.4 ± 4.5 liters per hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98ad5af1-bde6-4137-a599-b6354d664da4 (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The volume of distribution (V dss /F) of methylergonovine was calculated to be 56.1 ± 17.0 liters, and the plasma clearance (CLp/F) was calculated to be 14.4 ± 4.5 liters per hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a6fe76c-d709-419e-885e-fa2ce07df27b (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The volume of distribution (Vd SS /F) of methylergonovine was calculated to be 56.1 ± 17.0 liters, and the plasma clearance (CLp/F) was calculated to be 14.4 ± 4.5 liters per hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a318b77-d280-4571-992f-82e2e0a57c9b (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The volume of distribution (Vd ss /F) of methylergonovine was calculated to be 56.1 ± 17.0 liters, and the plasma clearance (CLp/F) was calculated to be 14.4 ± 4.5 liters per hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4c48277-eb9e-6150-e053-2a95a90ab21d (opens source in a new tab)
Methylergonovine label
Version not recorded · Effective date not recorded
The volume of distribution (VdSS/F) of methylergonovine was calculated to be 56.1 ± 17.0 liters, and the plasma clearance (CLp/F) was calculated to be 14.4 ± 4.5 liters per hour.
Projected row 975
- Medicine slug
- methylphenidate
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 86
- Source count
- 17
- Agreement rate
- 0.647059
- Recorded readings
22 ± 8 %
- Numeric value
- 22
- Unit
- %
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35be77db-fbe3-487e-a220-a08a11aaec28 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of methylphenidate is 22 ± 8 % for the d-enantiomer and 5 ± 3 % for the l-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5db854a-1c77-4faf-9e60-daf9c9b6cfa0 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of methylphenidate in children was 22 ± 8% for d-methylphenidate and 5 ± 3% for l- methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c614cf55-b462-4f7e-b19c-6d22a47e509f (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of methylphenidate is 22 ± 8% for the d-enantiomer and 5 ± 3% for the l-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:238ff743-4f25-43a3-87ac-6559d12a9d49 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of methylphenidate is 22 ± 8 % for the d-enantiomer and 5 ± 3 % for the l-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6fb2750-cdab-4749-ba0d-7534840a5892 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of methylphenidate is 22 ± 8 % for the d-enantiomer and 5 ± 3 % for the l-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:778190da-1528-4def-94bf-ee23ee5268a5 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
This was below the threshold of clinical concern and there was no evident exposure response relationship. 12.3 Pharmacokinetics Absorption The absolute bioavailability of methylphenidate is 22 ± 8 % for the d-enantiomer and 5 ± 3 % for the l-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:034fb7cd-e183-475e-8beb-64fd88facc8f (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of methylphenidate in children was 22 ± 8% for d-methylphenidate and 5 ± 3% for l- methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0bf0835-6a2f-4067-a158-8b86c4b0668a (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of methylphenidate is 22 ± 8 % for the d-enantiomer and 5 ± 3 % for the l-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bf37f9f-29cf-4b09-9c81-eb369e35a042 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
This was below the threshold of clinical concern and there was no evident exposure response relationship. 12.3 Pharmacokinetics Absorption The absolute bioavailability of methylphenidate is 22 ± 8 % for the d-enantiomer and 5 ± 3 % for the l-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8c14df4-ac05-d69d-9308-58a51d568329 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of methylphenidate in children was 22 ± 8% for d-methylphenidate and 5 ± 3% for l- methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a89b390-0cd5-45cb-9e70-20de44652c56 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of methylphenidate is 22 ± 8 % for the d-enantiomer and 5 ± 3 % for the l-enantiomer.
22%
- Numeric value
- 22
- Unit
- %
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:effd952d-ac94-47bb-b107-589a4934dcca (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of methylphenidate in children was 22% ± 8% for d-methylphenidate and 5% ± 3% for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27ea91ad-f64e-43d7-ab10-6f988bca5379 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of methylphenidate in children was 22% ± 8% for d-methylphenidate and 5% ± 3% for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44386394-d2a3-4483-abe1-6c5c634cc501 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of methylphenidate in children was 22% ± 8% for d-methylphenidate and 5% ± 3% for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f8983ce-71b8-4c62-830d-e4692ddededa (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of methylphenidate in children was 22% ± 8% for d-methylphenidate and 5% ± 3% for l-methylphenidate.
102%
- Numeric value
- 102
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7a7ffd1-bc30-4db8-8391-dddf76acd639 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The relative bioavailability is 102%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ecbb4a30-21ac-42e1-b4e9-6c35344ffc45 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The relative bioavailability is 102%.
Projected row 976
- Medicine slug
- methylphenidate
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 86
- Source count
- 38
- Agreement rate
- 0.447368
- Recorded readings
3.6 hours
- Numeric value
- 3.6
- Unit
- hours
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7124df7e-6273-a68d-6e35-dc06122d8686 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85ef422d-af27-4126-9841-6892af1871d6 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18024571-4505-6d51-e063-6294a90a1972 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b07150db-fd99-4400-bb83-b3a7544a917a (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22e5ddfa-7264-fbb1-e063-6394a90a6483 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd8d7b6e-c23d-4e16-bb53-959e9127ebc6 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1b0f2ff-d9df-42ab-b471-226ecf97e075 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9af3104-172d-4975-9301-b9fe7db9ef12 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44737c1d-fe75-409e-8a58-591696d3d7aa (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a88218c-5b18-4220-8f56-526de1a276cd (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d1f5aff-5d39-496c-b5ed-7f3c70ec641c (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:768bf181-d0d8-49e5-9c87-cacbb069e0b2 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6581305-cd1e-4171-8c1b-e184c7bde033 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd2c1226-fa19-4734-b62d-89fea73dcb0d (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a29687b-5294-4b27-a556-514b092a877d (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean half-life was about 3.6 hours.
2.7 hours
- Numeric value
- 2.7
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:213ca0da-dde8-48ee-ac8c-c66558e6f62d (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life (t½) of methylphenidate was 2.7 hours following administration of 20 mg methylphenidate hydrochloride oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cf1b26b-199d-4c7f-ab64-4805a9def2cc (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life (t½) of methylphenidate was 2.7 hours following administration of 20 mg methylphenidate hydrochloride oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:298fb86d-7d94-49e1-b743-3e7801122422 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life (t½) of methylphenidate was 2.7 hours following administration of 20 mg methylphenidate hydrochloride oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83e70f8f-18dd-45fc-8bc5-4b8f7f23439e (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life (t1/2) of methylphenidate was 2.7 hours following administration of 20 mg methylphenidate hydrochloride oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea5a6d4e-60ba-46f3-b314-3c7a970b377d (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life (t½) of methylphenidate was 2.7 hours following administration of 20 mg methylphenidate hydrochloride oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e3c22d9-71d9-46a7-b315-8021c94c4bec (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life (t ½ ) of methylphenidate was 2.7 hours following administration of 20 mg Methylin Oral Solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57fd619e-687d-403c-a77a-3dc3a1bab65a (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life (t ½ ) of methylphenidate was 2.7 hours following administration of 20 mg Methylphenidate Hydrochloride Oral Solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad3a3865-952e-46cf-8387-1228e2375312 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life (t1/2) of methylphenidate was 2.7 hours following administration of 20 mg methylphenidate hydrochloride oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fa3da25-13aa-4ee3-acf5-cd505f4688d0 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life (t ½ ) of methylphenidate was 2.7 hours following administration of 20 mg methylphenidate hydrochloride oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9c31526-d486-433c-9b3c-7a12765afe94 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life (t½) of methylphenidate was 2.7 hours following administration of 20 mg methylphenidate hydrochloride oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e817377f-bc72-415a-acd2-7136746b2479 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life (t 1/2 ) of methylphenidate was 2.7 hours following administration of 20 mg methylphenidate hydrochloride oral solution.
3.5 hours
- Numeric value
- 3.5
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5db854a-1c77-4faf-9e60-daf9c9b6cfa0 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
In studies with methylphenidate hydrochloride extended-release capsules (LA) and methylphenidate hydrochloride tablets in adults, methylphenidate from methylphenidate hydrochloride tablets is eliminated from plasma with an average half-life of about 3.5 hours, (range, 1.3 to 7.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:effd952d-ac94-47bb-b107-589a4934dcca (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
In studies with Ritalin LA and Ritalin tablets in adults, methylphenidate from Ritalin tablets is eliminated from plasma with an average half-life of about 3.5 hours, (range, 1.3 to 7.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27ea91ad-f64e-43d7-ab10-6f988bca5379 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
In studies with methylphenidate hydrochloride extended-release capsules and methylphenidate hydrochloride tablets in adults, methylphenidate from methylphenidate hydrochloride tablets is eliminated from plasma with an average half-life of about 3.5 hours, (range, 1.3 to 7.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44386394-d2a3-4483-abe1-6c5c634cc501 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
In studies with methylphenidate hydrochloride extended-release capsules and methylphenidate hydrochloride tablets in adults, methylphenidate from methylphenidate hydrochloride tablets is eliminated from plasma with an average half-life of about 3.5 hours, (range, 1.3 to 7.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:034fb7cd-e183-475e-8beb-64fd88facc8f (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
In studies with methylphenidate hydrochloride extended-release capsules and methylphenidate hydrochloride tablets in adults, methylphenidate from methylphenidate hydrochloride tablets is eliminated from plasma with an average half-life of about 3.5 hours, (range 1.3 to 7.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f8983ce-71b8-4c62-830d-e4692ddededa (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
In studies with methylphenidate hydrochloride extended-release capsules and methylphenidate hydrochloride tablets in adults, methylphenidate from methylphenidate hydrochloride tablets is eliminated from plasma with an average half-life of about 3.5 hours, (range, 1.3 to 7.7 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8c14df4-ac05-d69d-9308-58a51d568329 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
In studies with methylphenidate hydrochloride extended-release capsules (LA) and methylphenidate hydrochloride tablets in adults, methylphenidate from methylphenidate hydrochloride tablets is eliminated from plasma with an average half-life of about 3.5 hours, (range, 1.3 to 7.7 hours).
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5cb0740-813f-4dce-8c29-d7680c66e77c (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life (t ½ ) of methylphenidate was 3 hours following administration of 20 mg Methylphenidate Hydrochloride Chewable Tablet.
4 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33f70f58-c871-42c8-8adb-345caeafefcd (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean plasma terminal elimination half-life of methylphenidate was about 4 hours in healthy volunteers following a single 51.8 mg dose administration.
5.2 hours
- Numeric value
- 5.2
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:defc1205-8e90-4b1e-b862-05e4c35c7364 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The mean plasma terminal elimination half-life of methylphenidate was about 5.2 hours in healthy volunteers following a single 40 mg dose administration.
Projected row 977
- Medicine slug
- methylphenidate
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 86
- Source count
- 17
- Agreement rate
- 1
- Recorded readings
10%
- Numeric value
- 10
- Unit
- %
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:213ca0da-dde8-48ee-ac8c-c66558e6f62d (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be59f8b4-7842-42cc-9559-bfa747f0baa5 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cf1b26b-199d-4c7f-ab64-4805a9def2cc (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e45c75dc-d381-475b-b649-a871c8a36e60 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10aa0dc0-bd0e-4927-a19a-8722d78ad67d (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:298fb86d-7d94-49e1-b743-3e7801122422 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5cb0740-813f-4dce-8c29-d7680c66e77c (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83e70f8f-18dd-45fc-8bc5-4b8f7f23439e (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea5a6d4e-60ba-46f3-b314-3c7a970b377d (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e3c22d9-71d9-46a7-b315-8021c94c4bec (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57fd619e-687d-403c-a77a-3dc3a1bab65a (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29f06562-6b6a-4ca6-b62e-d08a45fb3dd4 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad3a3865-952e-46cf-8387-1228e2375312 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fa3da25-13aa-4ee3-acf5-cd505f4688d0 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9c31526-d486-433c-9b3c-7a12765afe94 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e11e093-4ff3-4bed-8fe9-3ee460b47303 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e817377f-bc72-415a-acd2-7136746b2479 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding is 10% to 33%.
Projected row 978
- Medicine slug
- methylphenidate
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 86
- Source count
- 30
- Agreement rate
- 0.366667
- Recorded readings
1 to 2 hours
- Numeric value
- 1
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:213ca0da-dde8-48ee-ac8c-c66558e6f62d (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
tion of 20 mg methylphenidate hydrochloride oral solution and 20 mg tablet of methylphenidate hydrochloride in healthy volunteers under fasted conditions, time to peak plasma concentration (T max ) of methylphenidate was at 1 to 2 hours after dosing, and: • The mean peak plasma concentration (C max ) of methylphenidate was 9.1 ng/mL and 9.8 ng/mL, respectively. • The mean area under concentration
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cf1b26b-199d-4c7f-ab64-4805a9def2cc (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
ation of 20 mg methylphenidate hydrochloride oral solution and 20 mg tablet of methylphenidate hydrochloride in healthy volunteers under fasted conditions, time to peak plasma concentration (Tmax) of methylphenidate was at 1 to 2 hours after dosing, and: The mean peak plasma concentration (Cmax) of methylphenidate was 9.1 ng/mL and 9.8 ng/mL, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:298fb86d-7d94-49e1-b743-3e7801122422 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
tion of 20 mg methylphenidate hydrochloride oral solution and 20 mg tablet of methylphenidate hydrochloride in healthy volunteers under fasted conditions, time to peak plasma concentration (T max ) of methylphenidate was at 1 to 2 hours after dosing, and: • The mean peak plasma concentration (C max ) of methylphenidate was 9.1 ng/mL and 9.8 ng/mL, respectively. • The mean area under concentration
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83e70f8f-18dd-45fc-8bc5-4b8f7f23439e (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
tion of 20 mg methylphenidate hydrochloride oral solution and 20 mg tablet of methylphenidate hydrochloride in healthy volunteers under fasted conditions, time to peak plasma concentration (T max ) of methylphenidate was at 1 to 2 hours after dosing, and: The mean peak plasma concentration (C max ) of methylphenidate was 9.1 ng/mL and 9.8 ng/mL, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea5a6d4e-60ba-46f3-b314-3c7a970b377d (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
tion of 20 mg methylphenidate hydrochloride oral solution and 20 mg tablet of methylphenidate hydrochloride in healthy volunteers under fasted conditions, time to peak plasma concentration (T max ) of methylphenidate was at 1 to 2 hours after dosing, and: • The mean peak plasma concentration (C max ) of methylphenidate was 9.1 ng/mL and 9.8 ng/mL, respectively. • The mean area under concentration
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e3c22d9-71d9-46a7-b315-8021c94c4bec (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following a single dose administration of 20 mg Methylin and 20 mg tablet of methylphenidate hydrochloride in healthy volunteers under fasted conditions, time to peak plasma concentration (T max ) of methylphenidate was at 1 to 2 hours after dosing, and: The mean peak plasma concentration (C max ) of methylphenidate was 9.1 ng/mL and 9.8 ng/mL, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57fd619e-687d-403c-a77a-3dc3a1bab65a (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
tion of 20 mg methylphenidate hydrochloride oral solution and 20 mg tablet of methylphenidate hydrochloride in healthy volunteers under fasted conditions, time to peak plasma concentration (T max ) of methylphenidate was at 1 to 2 hours after dosing, and: The mean peak plasma concentration (C max ) of methylphenidate was 9.1 ng/mL and 9.8 ng/mL, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad3a3865-952e-46cf-8387-1228e2375312 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
tion of 20 mg methylphenidate hydrochloride oral solution and 20 mg tablet of methylphenidate hydrochloride in healthy volunteers under fasted conditions, time to peak plasma concentration (T max ) of methylphenidate was at 1 to 2 hours after dosing, and: The mean peak plasma concentration (C max ) of methylphenidate was 9.1 ng/mL and 9.8 ng/mL, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fa3da25-13aa-4ee3-acf5-cd505f4688d0 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
tion of 20 mg methylphenidate hydrochloride oral solution and 20 mg tablet of methylphenidate hydrochloride in healthy volunteers under fasted conditions, time to peak plasma concentration (T max ) of methylphenidate was at 1 to 2 hours after dosing, and: The mean peak plasma concentration (C max ) of methylphenidate was 9.1 ng/mL and 9.8 ng/mL, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9c31526-d486-433c-9b3c-7a12765afe94 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
tion of 20 mg methylphenidate hydrochloride oral solution and 20 mg tablet of methylphenidate hydrochloride in healthy volunteers under fasted conditions, time to peak plasma concentration (T max ) of methylphenidate was at 1 to 2 hours after dosing, and: • The mean peak plasma concentration (C max ) of methylphenidate was 9.1 ng/mL and 9.8 ng/mL, respectively. • The mean area under concentration
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e817377f-bc72-415a-acd2-7136746b2479 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
tion of 20 mg methylphenidate hydrochloride oral solution and 20 mg tablet of methylphenidate hydrochloride in healthy volunteers under fasted conditions, time to peak plasma concentration (T max ) of methylphenidate was at 1 to 2 hours after dosing, and: The mean peak plasma concentration (C max ) of methylphenidate was 9.1 ng/mL and 9.8 ng/mL, respectively.
1 to 3 hours
- Numeric value
- 1
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5db854a-1c77-4faf-9e60-daf9c9b6cfa0 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The initial rate of absorption for methylphenidate hydrochloride extended-release capsules (LA) is similar to that of methylphenidate hydrochloride tablets as shown by the similar rate parameters between the 2 formulations, i.e., initial lag time (T lag ), first peak concentration (C max1 ), and time to the first peak (T max1 ), which is reached in 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:effd952d-ac94-47bb-b107-589a4934dcca (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The initial rate of absorption for Ritalin LA is similar to that of Ritalin tablets as shown by the similar rate parameters between the 2 formulations, i.e., initial lag time (T lag ), first peak concentration (C max1 ), and time to the first peak (T max1 ), which is reached in 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27ea91ad-f64e-43d7-ab10-6f988bca5379 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The initial rate of absorption for methylphenidate hydrochloride extended-release capsules is similar to that of methylphenidate hydrochloride tablets as shown by the similar rate parameters between the 2 formulations, i.e., initial lag time (T lag ), first peak concentration (C max1 ), and time to the first peak (T max1 ), which is reached in 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44386394-d2a3-4483-abe1-6c5c634cc501 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The initial rate of absorption for methylphenidate hydrochloride extended-release capsules is similar to that of methylphenidate hydrochloride tablets as shown by the similar rate parameters between the 2 formulations, i.e., initial lag time (T lag ), first peak concentration (C max1 ), and time to the first peak (T max1 ), which is reached in 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:034fb7cd-e183-475e-8beb-64fd88facc8f (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The initial rate of absorption for methylphenidate hydrochloride extended-release capsules are similar to that of methylphenidate hydrochloride tablets as shown by the similar rate parameters between the 2 formulations, i.e., initial lag time (T lag ), first peak concentration (C max1 ), and time to the first peak (T max1 ), which is reached in 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f8983ce-71b8-4c62-830d-e4692ddededa (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The initial rate of absorption for methylphenidate hydrochloride extended-release capsules is similar to that of methylphenidate hydrochloride tablets as shown by the similar rate parameters between the 2 formulations, i.e., initial lag time (T lag ), first peak concentration (C max1 ), and time to the first peak (T max1 ), which is reached in 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8c14df4-ac05-d69d-9308-58a51d568329 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The initial rate of absorption for methylphenidate hydrochloride extended-release capsules (LA) is similar to that of methylphenidate hydrochloride tablets as shown by the similar rate parameters between the 2 formulations, i.e., initial lag time (T lag ), first peak concentration (C max1 ), and time to the first peak (T max1 ), which is reached in 1 to 3 hours.
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7293dffd-eb01-43d4-b9c4-04f79bec180c (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Food Effect In a study in adult volunteers investigating the effects of a high-fat meal on the bioavailability of methylphenidate hydrochloride chewable tablets at a dose of 20 mg, the presence of food delayed the peak concentrations by approximately 1 hour (1.5 hours, fasted and 2.4 hours, fed).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5cb0740-813f-4dce-8c29-d7680c66e77c (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Effect of Food In a study in adult volunteers investigating the effects of a high-fat meal on the bioavailability of Methylphenidate Hydrochloride Chewable Tablets at a dose of 20 mg, the presence of food delayed the peak concentrations by approximately 1 hour (1.5 hours, fasted and 2.4 hours, fed).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2dc2109-44a6-4797-b04e-18761dd9d45a (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
In a study in adult volunteers to investigate the effects of a high-fat meal on the bioavailability of QUILLIVANT XR at a dose of 60 mg, the presence of food reduced the time to peak concentration by approximately 1 hour (fed: 4 hours vs. fasted: 5 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91833146-fa95-471a-8b8d-6d36a2db5c9a (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Food Effect In a study in adult volunteers investigating the effects of a high-fat meal on the bioavailability of methylphenidate hydrochloride chewable tablets at a dose of 20 mg, the presence of food delayed the peak concentrations by approximately 1 hour (1.5 hours, fasted and 2.4 hours, fed).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bfe50ed-171f-4c40-bc0b-20c68e8e2025 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Food Effect In a study in adult volunteers investigating the effects of a high-fat meal on the bioavailability of methylphenidate hydrochloride chewable tablets at a dose of 20 mg, the presence of food delayed the peak concentrations by approximately 1 hour (1.5 hours, fasted and 2.4 hours, fed).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb73cd3e-aa7c-4f7e-826d-75e71fb6d1e0 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Food Effect In a study in adult volunteers investigating the effects of a high-fat meal on the bioavailability of methylphenidate hydrochloride chewable tablets at a dose of 20 mg, the presence of food delayed the peak concentrations by approximately 1 hour (1.5 hours, fasted and 2.4 hours, fed).
4 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c312c31-3198-4775-91ab-294e0b4b9e7f (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
When applied to inflamed skin, lag time is no greater than 1 hour, T max is 4 hours, and both C max and AUC are approximately 3-fold higher.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1643b6a5-80da-4d4f-8c5f-feb907875702 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
When applied to inflamed skin, lag time is no greater than 1 hour, T max is 4 hours, and both C max and AUC are approximately 3-fold higher.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
When applied to inflamed skin, lag time is no greater than 1 hour, Tmax is 4 hours, and both Cmax and AUC are approximately 3-fold higher.
5.5 hours
- Numeric value
- 5.5
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Mean time to reach peak plasma concentrations of RELEXXII occurs at 5.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd8d7b6e-c23d-4e16-bb53-959e9127ebc6 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Mean time to reach peak plasma concentrations of methylphenidate hydrochloride extended-release tablets occurs at 5.5 hours.
2.5 hours
- Numeric value
- 2.5
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d95dede0-b1ff-4489-8f91-3bbe122852bf (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
Figure Food Effects Compared to the fasted state, JORNAY PM taken with a high-fat meal at night exhibited similar mean AUC 0-∞ , a 14% lower mean C max , and a median T max extended by approximately 2.5 hours.
Projected row 979
- Medicine slug
- methylphenidate
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 86
- Source count
- 52
- Agreement rate
- 1
- Recorded readings
2.65 ± 1.11 L/kg
- Numeric value
- 2.65
- Unit
- L/kg
- Source records
- 52
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 52 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98be5c84-b348-6b8e-e053-2995a90ae4cc (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:213ca0da-dde8-48ee-ac8c-c66558e6f62d (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e97c9f3-956c-416a-a7c2-68bb92053ce5 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11L/kg for d-methylphenidate and 1.80 ± 0.91L/kg for l- methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed004cf0-eb23-43d2-96dc-20c4ad63824f (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be59f8b4-7842-42cc-9559-bfa747f0baa5 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d- methylphenidate and 1.80 ± 0.91 L/kg for l- methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cf1b26b-199d-4c7f-ab64-4805a9def2cc (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35be77db-fbe3-487e-a220-a08a11aaec28 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l -methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e45c75dc-d381-475b-b649-a871c8a36e60 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d- methylphenidate and 1.80 ± 0.91 L/kg for l- methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5db854a-1c77-4faf-9e60-daf9c9b6cfa0 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d- methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10aa0dc0-bd0e-4927-a19a-8722d78ad67d (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d- methylphenidate and 1.80 ± 0.91 L/kg for l- methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:298fb86d-7d94-49e1-b743-3e7801122422 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec8a8896-077d-4dee-9e10-97172512c5ed (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d- methylphenidate and 1.80 ± 0.91 L/kg for l- methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11f4ec97-ed86-48b5-af3a-446b882294cb (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l -methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1da9dc9e-7e8e-457a-93d4-9c2aee434e69 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l -methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:981a2ad8-33f7-4678-9162-9df9685bd4a6 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c614cf55-b462-4f7e-b19c-6d22a47e509f (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l -methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c7d7e6c-4e96-4d18-8dca-203ef50766ec (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d -methylphenidate and 1.80 ± 0.91 L/kg for l -methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5cb0740-813f-4dce-8c29-d7680c66e77c (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83e70f8f-18dd-45fc-8bc5-4b8f7f23439e (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:238ff743-4f25-43a3-87ac-6559d12a9d49 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d- methylphenidate and 1.80 ± 0.91 L/kg for l- methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:effd952d-ac94-47bb-b107-589a4934dcca (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9beb136f-020b-4631-b989-c1d26a9846f7 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l -methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13a17c5a-bba7-4c5a-a4f9-2141bcdffa1a (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l -methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea5a6d4e-60ba-46f3-b314-3c7a970b377d (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e3c22d9-71d9-46a7-b315-8021c94c4bec (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27ea91ad-f64e-43d7-ab10-6f988bca5379 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.8 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57fd619e-687d-403c-a77a-3dc3a1bab65a (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29f06562-6b6a-4ca6-b62e-d08a45fb3dd4 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d- methylphenidate and 1.80 ± 0.91 L/kg for l- methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6fb2750-cdab-4749-ba0d-7534840a5892 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l -methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad3a3865-952e-46cf-8387-1228e2375312 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fa3da25-13aa-4ee3-acf5-cd505f4688d0 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94dc74d4-b4ef-45bc-b502-54ec692e9bd5 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d- methylphenidate and 1.80 ± 0.91 L/kg for l- methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f3c91e6-4576-4326-bdab-7d8fb7c09bb8 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b77128b3-fce4-4bee-bdad-5fe4af9d612d (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l -methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44386394-d2a3-4483-abe1-6c5c634cc501 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb9b7377-d918-43fb-8e82-d14c85ed64a8 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:371346d1-ac7e-491c-a010-ad29cb3d567a (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l -methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a22dd9b-9b48-4c96-8b20-0d20131521dc (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d -methylphenidate and 1.80 ± 0.91 L/kg for l -methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:778190da-1528-4def-94bf-ee23ee5268a5 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l- methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cc16009-44ad-4055-ac76-efa282f1ff47 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l -methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:034fb7cd-e183-475e-8beb-64fd88facc8f (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d- methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9c31526-d486-433c-9b3c-7a12765afe94 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0bf0835-6a2f-4067-a158-8b86c4b0668a (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l -methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f8983ce-71b8-4c62-830d-e4692ddededa (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bf37f9f-29cf-4b09-9c81-eb369e35a042 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate Elimination The systemic clearance is 0.40 ± 0.12 L/h/kg for d-methylphenidate and 0.73 ± 0.28 L/h/kg for l- methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e11e093-4ff3-4bed-8fe9-3ee460b47303 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec3d9304-13bc-4f0b-bf14-1a1ea824bd91 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d- methylphenidate and 1.80 ± 0.91 L/kg for l- methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c87a2000-b75c-41df-8497-7e00a9b41ad4 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l -methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e817377f-bc72-415a-acd2-7136746b2479 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8c14df4-ac05-d69d-9308-58a51d568329 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d- methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a89b390-0cd5-45cb-9e70-20de44652c56 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d -methylphenidate and 1.80 ± 0.91 L/kg for l -methylphenidate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45d33807-88b2-4b42-9c86-e5b05d7adec1 (opens source in a new tab)
Methylphenidate label
Version not recorded · Effective date not recorded
The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.8 ± 0.91 L/kg for l-methylphenidate.
Projected row 980
- Medicine slug
- metoclopramide
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 66
- Source count
- 65
- Agreement rate
- 1
- Recorded readings
80%
- Numeric value
- 80
- Unit
- %
- Source records
- 65
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 65 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cd1dc35-2fb2-4f1d-8769-24c3c3aa34fa (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Absorption Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide was 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b16ad17c-eeea-407e-91e4-36506e9aa698 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Increased rate of stomach emptying was observed with single oral doses of 10 mg. 12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc364325-dd39-4259-a348-3760eccdca4b (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7678bcd5-1071-0a9b-e053-2a91aa0a3853 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94e5acdf-f19c-749a-e053-2995a90ae451 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e12e98a-06fe-4b3c-bb64-f2701e195c74 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ±15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4ab34f2-25e6-47bd-9dde-1f4baf469f0d (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5345a125-0cee-472e-e063-6394a90aeb21 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:697ec7b1-945a-4a31-b585-f051dc246165 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50a3cf38-66dc-4fa5-8a45-adf959c987ab (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce367a41-89d3-45c2-aac2-36fce43062d0 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:917494a9-cff1-4ee6-9523-e112120373c5 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14114420-fee0-4850-b99e-cdb5f421cd33 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ±15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4046830f-4b87-5e6e-e063-6394a90aeeb8 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:373ba08b-33ad-49fc-28a7-928e89a65314 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e15905e0-e0f6-4c8b-ac19-59724d6c4bf0 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31da0c8b-8171-4bd2-9832-12ba85e36b37 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46dcafbc-9d50-316a-e054-00144ff88e88 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e34fea34-5fc5-4200-bc9d-f5e558023630 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ±15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de55c133-eb08-4a35-91a2-5dc093027397 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cccf04bd-7463-40b8-a41f-cb1093c358d7 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5345905d-18b0-1e42-e063-6394a90af745 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67024bbc-65d1-428d-a807-46647038daf6 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ±15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d7cd5a0-4a84-4084-e053-2a91aa0a686f (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ce3245f-7021-5135-e063-6394a90a7d95 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ±15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7eeaa7bc-c94f-47d0-94e5-e35ccadca19e (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cd4b274-6176-4e5b-9765-4f50763bd58f (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d31d815-50fa-4e78-8ebd-affc2514ce78 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4524146c-f588-083b-e063-6294a90ac977 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79754097-4514-297e-e053-2991aa0a4804 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40cf021d-5f2a-055c-e054-00144ff88e88 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:447dbb34-7903-4e6a-be31-48a0b0e0d2f5 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f50c8fb4-23c4-4762-95bb-e4ca7b289a4d (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58b3666f-ac0f-811e-e063-6394a90a8e04 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Increased rate of stomach emptying was observed with single oral doses of 10 mg. 12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:595439ae-cf01-821c-e063-6294a90af16a (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:797aad80-0597-42f8-99d5-39de180c3b5a (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d163182b-582d-df59-e053-2995a90a300b (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:264c4f48-51f4-458f-9e61-1adafdf604fc (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84ec68c1-efa0-4ed2-9fae-d0cc17b0a6b4 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ±15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6637cb78-d50a-4dbf-8fb7-b1b5102c5c5f (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5645a752-8868-4b51-8b59-48bb4276d763 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc4a13f8-1e9b-4c75-82c0-bcd11f0a9a66 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0034a97a-fb05-418a-a234-de278907cd2a (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ±15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58e70a1b-ac93-ff1d-e063-6394a90aa2da (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Increased rate of stomach emptying was observed with single oral doses of 10 mg. 12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74358569-7a24-4a59-a7fc-500d2341d6cb (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23f11d3c-1529-4bb6-a61e-e4bab1a3e98e (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55b3fecb-f60c-474b-9530-915b0e68bf85 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ecab710-8b7d-4903-80a8-de66562be55a (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45250bbc-d079-c362-e063-6294a90a56e0 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Increased rate of stomach emptying was observed with single oral doses of 10 mg. 12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4828095-94e0-4f71-901c-93837974c658 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49eb807b-fa34-3d84-e063-6394a90acfcf (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9530014b-c266-4015-9195-9f100d67317b (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ±15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b732ab-b859-7252-e053-2995a90af0d8 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15d616d7-2f4c-4882-a03c-fcc86c18f5f8 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:146803a1-199d-4789-b128-e974bdd03322 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f0a13cc-9346-4f4a-9a0d-b725045b01aa (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f2b17ea-c265-0cd4-e063-6294a90a9d88 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:998f1782-bbfa-469b-9fe1-c612e8588f70 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41d9ee49-d434-5f9f-e063-6294a90afe0b (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff067ac5-6efc-3e86-e6d5-590b2779491c (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cc8ca5b-8b71-4c77-a181-9ce154597b9a (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc739885-e10e-4bcb-a781-c726c518f3d1 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:548e83bc-898f-6b16-e063-6294a90a1755 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Increased rate of stomach emptying was observed with single oral doses of 10 mg. 12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ab8ddab-8226-4b5a-8774-308ed49d6bc4 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c143e210-4ce7-44e5-b1e2-bf0e6bfde485 (opens source in a new tab)
Metoclopramide label
Version not recorded · Effective date not recorded
Increased rate of stomach emptying was observed with single oral doses of 10 mg. 12.3 Pharmacokinetics Absorption Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=970Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.